Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647661 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL1647658 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL18722237 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL19538490 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL14707760 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL12038703 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL9650344 | 0.98 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL8059606 | 0.98 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL23430833 | 0.82 | LGALS8 (0.53) | PYGBCA12CA1CA2CA9 | |
| SCHEMBL21894588 | 0.82 | LGALS8 (0.53) | PYGBCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583247-A1 | METHOD AND SYSTEM FOR RECYCLING METAL OF LITHIUM SECONDARY BATTERY | SK Innovation Co., Ltd. (KR) | 2025-07-09 | — | — | EP | claimed |
| US-20250215522-A1 | METHOD AND SYSTEM FOR RECYCLING METAL OF LITHIUM SECONDARY BATTERY | SK INNOVATION CO., LTD. (KR) | 2025-07-03 | — | — | US | claimed |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2010-03-04 | — | — | US | claimed |
| US-5786468-A | NONIONIC SURFACTANTS DERIVED FROM CARBOHYDRATES FOR SHAMPOO, DEODORANTS OR CLEANING COMPOUNDS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1998-07-28 | — | — | US | claimed |
| EP-4583247-A1 | METHOD AND SYSTEM FOR RECYCLING METAL OF LITHIUM SECONDARY BATTERY | SK Innovation Co., Ltd. (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-20250215522-A1 | METHOD AND SYSTEM FOR RECYCLING METAL OF LITHIUM SECONDARY BATTERY | SK INNOVATION CO., LTD. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-12211979-B2 | Method for recovering active metal of lithium secondary battery | SK INNOVATION CO., LTD. (KR) | 2025-01-28 | — | — | US | disclosed |
| US-20230369670-A1 | METHOD FOR RECOVERING ACTIVE METAL OF LITHIUM SECONDARY BATTERY | SK INNOVATION CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4216338-A1 | METHOD FOR RECOVERING ACTIVE METAL OF LITHIUM SECONDARY BATTERY | SK Innovation Co., Ltd. (KR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022065702-A1 | METHOD FOR RECOVERING ACTIVE METAL OF LITHIUM SECONDARY BATTERY | 에스케이이노베이션 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| CN-104193674-A | Synthesis method of flunixin meglumine | JINAN JIULONG JIULONG PHARMACEUTICAL CO LTD | 2014-12-10 | — | — | CN | disclosed |
| EP-1116036-A1 | WATER-SOLUBLE FLUORESCENT SEMICONDUCTOR NANOCRYSTALS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-07-18 | — | — | EP | disclosed |
| US-5312934-A | Synthesis of sulfated polyhydroxy fatty acid amide surfactants | THE PROCTER & GAMBLE COMPANY (US) | 1994-05-17 | — | — | US | disclosed |
| US-5298636-A | Dissolving surfactant in water, acylating with acid anhydride to eliminate unreacted N-alkylamino polyol | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| US-5254281-A | Hardness, lather | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1993019038-A1 | PROCESS FOR REDUCING THE LEVELS OF FATTY ACID CONTAMINANTS IN POLYHYDROXY FATTY ACID AMIDE SURFACTANTS | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-30 | — | — | WO | disclosed |
| EP-0556348-A1 | PROCESS FOR PREPARING N-ALKYL POLYHYDROXY AMINES IN AMINE AND AMINE/WATER SOLVENTS AND FATTY ACID AMIDES THEREFROM | THE PROCTER & GAMBLE COMPANY (US) | 1993-08-25 | — | — | EP | disclosed |
| US-5188769-A | Reacting by-product with ammonia or amine | THE PROCTER & GAMBLE COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
| WO-1993003004-A1 | PROCESS FOR PREPARING N-ALKYL POLYHYDROXYALKYL AMINES IN AQUEOUS/HYDROXY SOLVENTS | THE PROCTER & GAMBLE COMPANY (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1992008687-A1 | PROCESS FOR PREPARING N-ALKYL POLYHYDROXY AMINES IN AMINE AND AMINE/WATER SOLVENTS AND FATTY ACID AMIDES THEREFROM | THE PROCTER & GAMBLE COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | TPH1, CACNA1G, CACNA1S | PYGB 125/4885GAA 1112/4885CA12 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.